濟民製藥(603222.SH):控股股東一致行動人張雪琴擬減持不超1%股份
格隆匯3月1日丨濟民製藥(603222.SH)公佈,公司於2021年3月1日收到控股股東及一致行動人張雪琴的《減持計劃吿知函》,截至本公吿披露日,張雪琴持有公司股份3906.92萬股,約佔公司股份總數的12.21%。張雪琴擬通過集中競價方式減持公司股份不超過320萬股,減持比例不超過公司總股本的1%。上述減持計劃將在自公吿之日起十五個交易日後的三個月內進行,且在任意連續90個自然日內,減持股份的總數不超過公司總股本的1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.